April 23 (Reuters) - Drug developer Inovio Pharmaceuticals INO.O said on Friday the U.S. government had stopped funding for a late-stage study testing its COVID-19 vaccine candidate, due to the increasing availability of authorized vaccines in the country.
(Reporting by Manojna Maddipatla in Bengaluru; Editing by Amy Caren Daniel)
((manojna.kalyani@thomsonreuters.com; +91 8061822700;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
